Amicus Therapeutics filings document the former public company’s rare-disease biotechnology business, common stock registration, operating results, governance matters, shareholder voting disclosures, material agreements, risk factors, clinical or regulatory updates, and capital-structure information. The filing record includes Form 8-K reports for quarterly results, corporate updates, and material events tied to its business and securities.
Later filings document Amicus Therapeutics’ completed merger, its survival as a wholly owned subsidiary of BioMarin Pharmaceutical Inc., the removal of its common stock from Nasdaq listing through Form 25, and the termination or suspension of Exchange Act reporting obligations through Form 15. These documents record the company’s transition from a Nasdaq-listed issuer to a subsidiary within BioMarin.
The Vanguard Group amended its Schedule 13G/A to report 0% beneficial ownership of Amicus Therapeutics Inc common stock. The filing states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The Schedule 13G/A records Amount beneficially owned: 0 and Percent of class: 0%, with the amendment signed on 03/26/2026.
Amicus Therapeutics President and CEO Bradley L. Campbell sold 22,500 shares of common stock in an open-market transaction. The sale took place at a weighted average price of $14.3484 per share on March 2, 2026, with individual trade prices ranging from $14.34 to $14.37. After this transaction, he continues to hold 998,680 shares of Amicus Therapeutics common stock directly.
Amicus Therapeutics reported that its stockholders approved the company’s pending acquisition by BioMarin Pharmaceutical at a special meeting held on March 3, 2026. As of the January 28, 2026 record date, 313,918,463 shares of Amicus common stock were eligible to vote, and 234,785,243 shares, or about 74.79% of outstanding shares, were represented in person or by proxy.
Stockholders adopted the Agreement and Plan of Merger between Amicus, BioMarin and Lynx Merger Sub 1, Inc., with 234,593,492 votes for, 119,194 against and 72,557 abstentions. They also approved, on a non-binding advisory basis, certain merger-related compensation for named executive officers, with 209,150,012 votes for, 24,282,220 against and 1,353,011 abstentions.
The approval of the merger proposal satisfies the stockholder approval condition in the merger agreement. The companies noted that the U.S. Federal Trade Commission had already granted early termination of the Hart-Scott-Rodino waiting period on February 11, 2026. Completion of the transaction remains subject to other customary closing conditions, including regulatory clearances in specified non-U.S. jurisdictions, and is expected to close in the second quarter of 2026.
Bradley Campbell reported sales of Common stock under 10b5-1 plans. The filing lists executed sales of 75,000 shares on 01/20/2026 for $1,073,182.50, 70,426 shares on 12/15/2025 for $763,509.39, and 7,500 shares on 12/15/2025 for $82,500.00.
The broker listed is Morgan Stanley Smith Barney LLC. The filing also shows 22,500 Restricted and Performance Stock Units dated 01/03/2021 as securities to be sold.
Amicus Therapeutics files its annual report highlighting a pending all-cash acquisition by BioMarin and continued growth in rare-disease therapies. Under a December 2025 merger agreement, BioMarin will acquire Amicus for $14.50 per share in cash, after which Amicus will become a wholly owned subsidiary and its stock will cease trading publicly, contingent on shareholder and regulatory approvals.
Commercial performance is led by Fabry drug Galafold, which generated $521.7 million in 2025 revenue, up $63.6 million year over year, and Pompe therapy Pombiliti + Opfolda, with $112.5 million in 2025 revenue, an increase of $42.3 million. Cash, cash equivalents and marketable securities totaled $293.5 million as of December 31 2025, supporting ongoing commercialization and pipeline work, including the U.S. license for Phase 3 kidney candidate DMX‑200. The company also emphasizes extensive patent protection, global regulatory approvals, and a long list of risk factors spanning merger completion, competition, pricing, regulation, financing needs, and reliance on third parties.
Amicus Therapeutics reported strong full-year 2025 growth and highlighted its pending acquisition by BioMarin. Net product revenue reached $634.2 million, up 20% year-over-year (17% at constant exchange rates), driven by Galafold at $521.7 million and Pombiliti + Opfolda at $112.5 million.
GAAP results improved to a net loss of $27.1 million, compared with larger losses in prior years, while non-GAAP net income was $96.8 million, or $0.31 per basic and diluted share. Cash and investments totaled $294 million, an increase of $44 million in 2025, and total assets were $949.9 million with stockholders’ equity of $274.2 million at year-end.
The company reiterated that the proposed acquisition by BioMarin is expected to close in Q2 2026, subject to closing conditions and approvals. Given the pending transaction, Amicus is not providing 2026 financial guidance and will not host its regular quarterly earnings conference call, directing investors instead to materials on its investor relations website.
Amicus Therapeutics, Inc. received an amended Schedule 13G/A (Amendment No. 3) from Wellington Management Group LLP and related entities reporting a small ownership stake in its common stock as of 12/31/2025.
The Wellington entities report beneficial ownership of 1,373,867 Amicus common shares, representing about 0.44% of the outstanding class. They have no sole voting or dispositive power, but report shared voting power over 1,034,976 shares and shared dispositive power over 1,373,867 shares.
The securities are owned of record by investment advisory clients of the Wellington investment advisers. Wellington certifies the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Amicus Therapeutics.
Amicus Therapeutics, Inc. received an amended Schedule 13G from William Blair Investment Management, LLC reporting its beneficial ownership of the company’s common stock. William Blair reports beneficial ownership of 10,627,717 shares of Amicus common stock, representing 3.4% of the outstanding shares as of 12/31/2025.
The firm has sole power to vote 10,321,526 shares and sole power to dispose of 10,627,717 shares, with no shared voting or dispositive power. William Blair certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Amicus Therapeutics.
Amicus Therapeutics has agreed to be acquired by BioMarin Pharmaceutical in an all-cash merger. Amicus stockholders are being asked to approve a Merger Agreement under which Lynx Merger Sub 1, a BioMarin subsidiary, will merge into Amicus, which will become a wholly owned BioMarin subsidiary.
At closing, each share of Amicus common stock will be converted into the right to receive $14.50 in cash per share, subject to applicable tax withholding and excluding shares with properly perfected appraisal rights. A virtual special meeting will be held on March 3, 2026, and holders of Amicus common stock at the January 28, 2026 record date may vote. The board unanimously recommends voting FOR the merger, the advisory compensation proposal, and the adjournment proposal. If approved and completed, Amicus will be delisted from Nasdaq, and stockholders will cease to own Amicus shares.
Amicus Therapeutics provided preliminary, unaudited 2025 financial estimates in connection with its proposed acquisition by BioMarin Pharmaceutical. As of December 31, 2025, Amicus estimates it held approximately $294 million in cash, cash equivalents and marketable securities. For the year ended December 31, 2025, it estimates total net product revenues of about $634 million, including roughly $522 million from Galafold® and $112 million from Pombiliti® + Opfolda®.
The company stresses these figures are preliminary, unaudited and subject to normal closing procedures, with its auditor Ernst & Young LLP providing no assurance. Amicus warns that actual results may differ, that the estimates do not include all information needed to understand full-year performance, and that they should be read together with risk factor and forward‑looking statement disclosures, especially in the context of the pending merger and related shareholder vote.